Bio-Rad Laboratories Inc.’s preparative protein purification system used in biopharmaceutical research doesn’t infringe six of a patent’s eight claims that Danaher Corp.’s Cytiva Sweden is asserting in a Delaware lawsuit, a federal judge ruled.
Judge Colm F. Connolly granted Bio-Rad’s motion for summary judgment that its Next Generation Chromatography, or NGC, system doesn’t infringe the six claims, according to an opinion Monday in the U.S. District Court for the District of Delaware. He agreed with Bio-Rad’s argument that Cytiva can’t prove indirect infringement because it failed to provide enough evidence of direct infringement of the claims after the patent’s July ...
Learn more about a Bloomberg Law subscription.
QUEENSLAND— A nurse in Australia has been formally reprimanded after admitting he submitted forged documents to Qantas (QF) in an attempt to secure a refund for a non-refundable airline ticket. Th...